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SUMMARY 
 
The neuronal ceroid lipofuscinoses (NCL) are inherited, progressive 
neurodegenerative disorders, with onset mostly in early childhood. They are 
characterised by intracellular accumulation of autofluorescent storage 
material, seen both in neurons and other cells. Three main types with 
childhood onset are recognised, infantile (INCL), late infantile (LINCL), 
and juvenile NCL (JNCL). The features common to these NCL types 
include visual failure, mental decline, epilepsy, and motor impairment. Thus 
far, no curative treatment is available and therapy is limited to symptomatic 
drug treatment and rehabilitation.  
 
In JNCL, the leading sign of the disease is visual failure, noticed around the 
age of 4-7 years. Later, mental decline becomes evident. To estimate the 
neuropsychological profile of blind patients with JNCL, a special 
neuropsychological test battery was developed. The test battery revealed 
uneven cognitive impairment. During the first 5 years after the diagnosis the 
ability to recognise similarities remains fairly good, while the digit memory 
span declines more quickly than the other sub-items. The special 
neuropsychological profile provides important guidelines for rehabilitation. 
 
The first epileptic seizure is noticed at a mean age of 10 years. The most 
common seizure types at the onset are generalised tonic-clonic seizures and 
complex partial seizures, whereas myoclonia are seen in the final stages of 
the disease. As the first antiepileptic drugs (AEDs), valproate and 
lamotrigine are equally effective, but adverse effects are less common with 
lamotrigine than with valproate therapy. Lamotrigine also seems to have a 
favourable effect on the general well-being. Clonazepam is found to be 
favourable as an add-on AED. 
 
ß-CIT-SPECT revealed decreased density of dopamine transporters, 
reflecting nigrostriatal dysfunction. The degree of dopaminergic 
hypofunction was related to the severity of the extrapyramidal symptoms. 
This justified a trial of dopaminergic drugs, with either levodopa or 
selegiline. In 1 year, the extrapyramidal symptoms decreased significantly 
in the patients on levodopa, as compared with the controls. However, there 
was considerable variation in this response. In the patients receiving 
selegiline, the response was less marked. As the thalamus and basal ganglia 
are also impaired by the disease process, the response to therapy is milder 
and probably also of shorter duration than that seen in Parkinson’s disease. 
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INTRODUCTION 
 
The neuronal ceroid lipofuscinoses  (NCL) are the most common group of 
progressive, neurodegenerative disorders of childhood. These diseases are 
assumed to occur world-wide, though their existence in the developing 
countries has not been documented. The childhood forms are inherited 
recessively, a gene defect having now been localised for each main type 
(Mole 1999). These disorders are characterised by intracellular 
accumulation of fluorescent ceroid and lipofuscin-like storage material.  
This storage material can be found both in neural and in extra-neural cells, 
although the symptoms mainly reflect the disease of the central nervous 
system (CNS). There is widespread loss of nerve cells, which in the cerebral 
cortex, is pronounced. 
 
The NCL disorders are classified as lysosomal diseases. In the main NCL 
types, the gene defect results in depletion of a protein, which either resides 
in a lysosome or is an unknown transmembrane protein. However, the 
precise pathogenesis still remains unknown. 
 
The clinical symptoms common to all the different childhood NCL types are 
impaired vision, mental deterioration, epilepsy, psychiatric problems, and 
extrapyramidal and pyramidal symptoms. In the different types, these 
symptoms may develop at different age and in a different order. The child’s 
condition gradually deteriorates and the disease eventually leads to 
premature death. 
 
As yet, there is no curative treatment. However, symptomatic drug treatment 
brings about some relief in most patients, and is widely used. Furthermore, 
as these diseases are characterised by multiple symptoms, polytherapy is 
often needed, though it may give rise to problems in the form of adverse 
effects and unwanted interactions. Therefore, a systematic evaluation of the 
symptoms and their current treatment was considered necessary. 
 
Although the drug treatment is important and brings about relief of the 
symptoms, the most important thing to keep in mind, in the treatment of 
these patients, is support for their families. Rehabilitation, in the form of 
adjustment courses, physical therapy, occupational therapy and speech 
therapy, forms an important part of this support. 
  
 
10
REVIEW OF THE LITERATURE 
 
 
1. NEURONAL CEROID LIPOFUSCINOSES (NCL) 
 
1.1. History 
 
In 1826 Otto Christian Stengel described four siblings with loss of vision 
and mental deterioration, these symptoms being noticed after 6 years of age 
(Goebel 1995). The siblings lived in a Norwegian mining town, and at first 
the surroundings were blamed for the disease. In the hope of preventing 
further loss of abilities, the younger siblings were removed from the area, 
but nevertheless the disease progressed. This is probably the first description 
of NCL disorders in the literature. 
 
Around the turn of the century, several descriptions of the disease were 
made. In 1896, Sachs introduced the term “amaurotic familial idiocy” (AFI), 
a group of diseases with infantile onset, characterised by blindness, 
psychomotor deterioration, and early death. In 1903, Batten described 
patients suffering from “family cerebral degeneration with macular change” 
with a later onset and separated these patients clinically from those with 
infantile onset AFI. In 1905, this distinction was confirmed by Spielmeyer, 
who published his findings on siblings suffering from “a special form of 
AFI”, and by Vogt, who described patients suffering from “juvenile AFI”. 
 
Although clinical differences were noticed between the different forms of 
AFI, they were still regarded as clinical variants of a uniform disease entity. 
Indeed, Schaffer’s pathogenetic studies (1905), in which accumulating lipid 
material was found in swollen nerve cells in all these diseases, supported 
this view of a uniform disease entity.  In the reports of Batten (1903, 1914), 
late infantile and juvenile onset AFI were not separated either.  
 
In 1908 Jansky described a special form of AFI with cerebellar atrophy. In a 
paper published 1 year later, Vogt observed that siblings suffering from late 
onset AFI usually manifested the symptoms of the disease in the same 
chronological order, but that marked differences in the course of the disease 
existed between different families. Furthermore, in 1913 Bielchowsky 
reported his clinical and pathological findings in three siblings with seizures 
manifesting at the age of 3.5 years and followed by rapid deterioration 
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characterised by dementia and blindness. He proposed that this was a late 
infantile AFI, separating it from the juvenile AFI.  
 
Patients with infantile onset AFI were long included in the group of patients 
with AFI, and it was not until 1931 that Sjögren, on clinical grounds, clearly 
separated the juvenile type of AFI from the infantile type. All of the 115 
patients described by Sjögren had AFI with the juvenile onset. Separation of 
the infantile onset AFI from forms of AFI with the later onset was supported 
by the isolation of ganglioside from the brains of patients with infantile AFI, 
presently known as Tay-Sachs disease (Klenk 1939). 
 
In 1963, Zeman and Alpert reported on autofluorescent lipopigments in 
patients with late onset AFI, which finally distinguished patients with AFI 
from patients with other storage disorders, including Tay-Sachs disease. 
Subsequently, Zeman and Dyken formed the concept of “neuronal ceroid 
lipofuscinoses”, based on the storage material resembling ceroid and 
lipofuscin, and separated the age-dependent types of the disease (Zeman et 
al. 1969, 1970).  
 
1.2. Classification and different NCL types 
 
The late infantile and juvenile NCL types were thus described in the 
beginning of the 20th century, first on the basis of the clinical course, and 
later also on the electronmicroscopic and neurophysiologic findings. 
Infantile NCL, different from the infantile onset AFI, was described in 1973 
by Santavuori et al. These are three main childhood onset NCL types. 
Thereafter, several variants of the three main types were described, but these 
were not confirmed to be independent diseases until the 1990s, when the 
gene loci were mapped (Table 1). In addition to the NCL types, several 
subtypes have also been described; these have the same gene defect as the 
main NCL type, but the clinical course differs. 
 
Thus, localisation of these genes explained the varying clinical course, but, 
on the other hand, also showed that, in clinically similar diseases, the gene 
locus can be in different chromosomes. Furthermore, even if the gene defect 
is the same, the clinical phenotype may vary, as in other genetic diseases.  
 
Along with identification of the genes causing the diseases, the molecular 
background is gradually starting to emerge, and lysosomal degradation 
appears to be implicated in the main childhood types of NCL. CLN1 and 
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CLN2 both encode lysosomal enzymes, whereas CLN3 and CLN5 encode 
membrane proteins of unknown function. 
 
_____________________________________________________________ 
 
Table 1. The gene loci of the neuronal ceroid lipofuscinoses (NCL) 
 __________________________________________________________________ 
 
Gene  Disease   Locus Reference 
_____________________________________________________________ 
 
?  Congenital NCL  ?  Martin et al. 1999 
CLN1 Infantile NCL  1p32  Järvelä et al. 1991  
CLN2 Classical LINCL  11p15 Sharp et al. 1997 
CLN3 Juvenile NCL  16p12 Eiberg et al. 1989 
CLN4 Adult onset NCL  ?  Berkovic et al. 1988 
CLN5 Finnish vLINCL  13q22 Savukoski et al. 1994 
CLN6 Variant LINCL  15q22 Sharp et al. 1997 
CLN7 Turkish vLINCL  ?  Williams et al. 1999 
CLN8 Northern epilepsy 8p23  Tahvanainen et al.  1994 
_____________________________________________________________ 
 
? = not known, LINCL = late infantile neuronal ceroid lipofuscinosis, vLINCL = variant 
late infantile neuronal ceroid lipofuscinosis 
 
Congenital neuronal ceroid lipofuscinosis 
 
A rare congenital form of AFI was described by Norman and Wood in 1941. 
This NCL type, not found in Finland, is characterised by severe, generalised 
neonatal convulsions. The progression of the disease is rapid, leading to 
death before the age of 7 weeks, though usually within the first days of life. 
Microcephaly is prominent (Kohlschutter and Lake 1999), and, using 
ultrasound, can be noticed already during pregnancy.  
 
Infantile neuronal ceroid lipofuscinosis (CLN1) 
 
Infantile NCL (INCL), also called Santavuori-Haltia disease, was first 
described by Santavuori et al. in 1973. The first symptoms manifest around 
the age of 1 year as muscular hypotonia, delayed motor and psychomotor 
development, and progressive microcephaly. Thereafter, retardation of all 
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skills sets in. Ataxia, irritability and sleep disorders are also common signs 
in the early phase. Visual failure is noticed between the ages of 12 and 22 
months and rapidly leads to blindness. Epileptic seizures and myoclonic 
jerks are prominent. The patient’s condition rapidly deteriorates, and by the 
age of 3 years, all cognitive and motor skills are lost. Death usually occurs 
between  8 and 11 years of age. 
 
The CLN1 gene codes for the palmitoyl protein thioesterase (PPT) (Järvelä 
et al. 1991, Vesa et al. 1995), a lysosomal enzyme with the ability to remove 
fatty acids from palmitoylated proteins in vivo (Camp and Hofmann 1993). 
 
In the literature, late infantile onset (Wisniewski et al. 1997, Das et. al. 
1998) and juvenile onset subtypes of INCL (Lake et al. 1996, Crow et al. 
1997, Mitchinson et al. 1998) have also been described. In these variant 
forms, the gene locus has been confirmed to be the INCL locus and the 
electronmicroscopic findings are identical to those of the classical INCL, 
but the onset of the disease is later. 
 
Classic late infantile neuronal ceroid lipofuscinosis (CLN2) 
 
Classic late infantile NCL (cLINCL, Jansky-Bielchowsky disease) was 
originally described by Jansky (1908) and Bielchowsky (1913), although 
they were unable to separate this type from the forms with later onset. The 
onset of the disease is noticed between the ages of 2 and 4 years, the first 
sign usually being epilepsy. Sometimes delayed speech may precede 
epilepsy. Additional symptoms include dementia, ataxia, and myoclonic 
jerks. Visual failure leads to blindness usually by 5 or 6 years of age. Death 
usually occurs between 6 and 15 years of age. Although the disease is rare 
in Finland, it is one of the most common NCL types in the United States and 
Canada. 
 
The CLN2 gene codes for a lysosomal enzyme tripeptidyl peptidase 1 
(TPP1), which removes the terminal amino acids from proteins undergoing 
lysosomal degradation (Sleat et al. 1997¸ Vines and Warburton 1999). 
 
A variant subtype, late onset LINCL, has been recognised in LINCL. In this 
subtype, the gene locus and the enzyme defects are identical to that of 
classical LINCL, but the onset of the disease occurs later and the clinical 
course is slower (Sleat et al. 1999). 
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Juvenile neuronal ceroid lipofuscinosis (CLN3) 
 
The juvenile type of NCL (JNCL) can be recognised in the descriptions of 
Stengel (1826), Batten (1903), Spielmeyer (1905), Vogt (1909), and Sjögren 
(1931). Thus, the disease is also known as Spielmeyer-Vogt-Sjögren’s 
disease, and in the American literature as Batten’s disease, although the 
latter name is sometimes used to refer all the childhood onset types of NCL. 
 
Children with JNCL are born healthy and, at first, the developmental 
milestones are reached normally. However, around the age of 5 years, visual 
failure is noticed. In the early school years, gradual psychomotor 
deterioration becomes evident, and around the age of 10 years, the first 
epileptic seizures occur. Extrapyramidal signs start to develop in 
adolescence, leading to impaired ability to move around. In girls with 
JNCL, common findings are acne, obesity, and hirsutism, and in both sexes 
psychiatric symptoms and sleep disturbances are seen. The disease leads to 
premature death between the ages of 16 and 35 years. (Santavuori 1988, 
Hofman et al. 1999). 
 
The CLN3 gene was localised to chromosome 16p12 (Eiberg et al. 1989, 
Gardiner et al. 1990). It encodes for a previously unknown transmembrane 
protein, localised to the lysosomes (The International Batten Disease 
Consortium 1995, Järvelä et al. 1999). 
  
World-wide, 81% of the chromosomes carry the major mutation, a 1.02 kb 
deletion (Järvelä et al. 1996). Patients with the major mutation on both 
chromosomes are homozygotes for the major mutation. On the other hand, 
those patients in whom the major mutation is found in one of the 
chromosomes and another mutation in the other, are compound 
heterozygotes. In Finland, the major mutation is further enriched, and 90% 
of the Finnish CLN3 chromosomes carry the major deletion (Järvelä et al. 
1996). Although the majority of the patients have the major mutation in at 
least one of the chromosomes,  one patient was recently found to have a rare 
mutation on both chromosomes  (Santavuori, personal communication). 
 
In JNCL also, variants of the classical phenotype have been described. 
These consist mainly of patients with a protracted clinical course, the 
leading sign usually being visual failure (Goebel 1993, Åberg et al. 1998, 
Lauronen et al. 1999). 
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Adult onset neuronal ceroid lipofuscinosis (CLN4)  
 
The adult form of NCL (ANCL) was first described by Kufs in 1925 as a 
late form of amaurotic idiocy. ANCL is considered to be rare, although it is 
possible that not all the cases have been diagnosed. On the other hand, a 
considerable proportion of the reported cases of ANCL are probably not true 
cases, but may represent one of the other forms of lipidosis (Berkovic et al. 
1988).  
 
Two separate forms of ANCL have been described (Berkovic et al. 1988). 
The clinical phenotype A (Kufs’ disease) is characterised by progressive 
myoclonic epilepsy, dementia, ataxia, and pyramidal and extrapyramidal 
symptoms. Vision is normal, but retinal degeneration may be noticed. In the 
clinical phenotype B (Parry disease, CLN4), on the other hand, behavioural 
changes, dementia, ataxia, facial dyskinesia and extrapyramidal signs are 
seen. Epileptic seizures may be noticed, though they are usually non-
progressive. Visual failure has not been reported in this subtype. 
 
In Kufs’ disease, autosomal recessive inheritance is seen, but in the Parry 
disease, autosomal dominant inheritance has been described, in contrast to 
all the other NCL types. However, the gene locus and the function of the 
mutated genes are still unknown.  
 
Finnish variant late infantile neuronal ceroid lipofuscinosis (CLN5) 
 
The Finnish variant type of late infantile NCL (vLINCLFinn) is seen almost 
exclusively in Finland. The first manifestations of the disease occur between 
the ages of 4 and 7 years. These manifestations usually are attention deficit, 
visuomotor difficulties, and motor clumsiness, and they are followed by 
mental retardation and visual failure (Santavuori et al. 1999). Other 
symptoms include epilepsy, myoclonic jerks, and ataxia. Death usually 
occurs between the ages of 14 and 36 years. The CLN5 codes for a 407 
aminoacid transmembrane protein, with an unknown function. 
 
Variant late infantile NCL (CLN6) 
 
Variant late infantile NCL (vLINCL), sometimes also called early juvenile 
NCL was first described by Lake and Cavanagh in 1978. This subtype also 
includes the so-called Czech variant LINCL (Elleder et al. 1997). The 
clinical course varies, but the first symptoms usually include motor delay, 
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ataxia, regression, dysarthria, seizures and myoclonia. Visual failure may 
occur early. The disease leads to early death between the ages of 5 and 12 
years. 
 
Turkish variant late infantile NCL (CLN7) 
 
In the process of characterising the genes responsible for the different types 
of LINCL, all the families of Turkish origin were found to have gene loci 
differing from the known NCL loci (Williams et al. 1999). This subtype was 
therefore named the Turkish variant LINCL (vLINCLTurk). The onset of 
symptoms accords with the other types of LINCL, the early features of the 
disease being seizures and motor problems. Visual failure has a variable 
onset, and in some cases may be the leading sign. Cognitive impairment 
follows the first symptoms. The exact gene locus has not been found yet.  
 
Northern Epilepsy (CLN8) 
 
Northern Epilepsy, also known as progressive epilepsy with mental 
retardation (EPMR), was first described by Hirvasniemi et al. in 1994 in 
patients from the Kainuu region in Finland. On the basis of the ultrastructure 
of the storage material and the immunocytochemistry, the disease was later 
found to be one of the NCL disorders (Herva et al. 2000). The clinical signs 
appear between the ages of 5 and 10 years as epileptic seizures and learning 
disability (Hirvasniemi et al. 1995). Seizure frequency increases towards 
puberty, but then gradually decreases again. Motor clumsiness becomes 
evident in early adulthood. In contrast to the other NCL disorders with 
childhood onset, visual loss does not occur in the early stage of the disease 
(Herva et al. 2000). The CLN8 gene codes for a 286 aminoacid 
transmembrane protein with an unknown function (Ranta et al. 1999). 
 
1.3. Epidemiology 
 
The NCL diseases have been reported in several western countries. Along 
with the mapping of the main NCL subtypes, the common disease 
haplotypes were revealed. The mutational analysis of these genes confirmed 
the existence of the so-called founder effect. This refers to random variation 
in the frequency of rare genes during the formation of a new subpopulation 
of limited size. Thus, if the founders forming the subpopulation included a 
member with a rare recessive allele, the frequency of this allele will be 
much higher in the subpopulation than outside it. 
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In Finland, the predominant NCL genes are CLN1, CLN3 and CLN5. 
Altogether 95% and 89% of the Finnish patients with CLN1 and CLN5,  
respectively, carry the major mutation on both chromosomes (Järvelä et al 
1991, Das et al. 1998, Savukoski et al. 1998). As regards CLN3, the major 
mutation (a 1.02 kb deletion) is also enriched in the Finnish population, and 
around 80% of the Finnish patients with CLN3 carry the major mutation on 
both chromosomes. Thus, around 90% of the chromosomes carry this 
mutation. World-wide, around 80% of the chromosomes of patients with 
JNCL carry this mutation. (The International Batten Disease Consortium 
1995, Munroe et al. 1997, Zhong et al. 1998). The reported incidence and 
prevalence rates are given in Table 2. 
 
_____________________________________________________________ 
 
Table 2. Incidence (a) and prevalence (b) rates for the main NCL types,  
given as  per 100,000 births (a) or 1,000,000 inhabitants (b)  
_____________________________________________________________ 
 
       INCL     LINCL1      JNCL  
   (a) (b)  (a) (b)  (a) (b)  
_________________________________________________________________________ 
 
Finland2  5.0  5.4  ? 3.2  4.8 12.2 
Sweden2  0.6 0.7  ? 0.5  2.2 4.6 
Norway2  ? 0.2  ? 0.7  3.7 6.5 
Denmark2  ? ?  ? ?  2.0 3.1 
Iceland2  ? ?  ? 3.8  7.0 11.0 
Germany3  ? ?  0.5 ?  0.7 ? 
Italy4   ? ?  0.4 ?  0.2 ? 
Netherlands5 ? ?  0.5 ?  1.5 ?
 
Canada6  ? ?  2.2 ?  0.6 ? 
_____________________________________________________________ 
 
1Incidence and prevalence rates for LINCL are given for the group comprising both classic 
and the variant form of LINCL. 2Uvebrant et al. 1997, 3Claussen et al. 1992, 4Cardona and 
Rosati 1995,  5Hofman and Taschner 1999, 6MacLeod et al. 1976.  ? = not known, NCL = 
neuronal ceroid lipofuscinosis, INCL = infantile neuronal ceroid lipofuscinosis, LINCL = 
late infantile neuronal ceroid lipofuscinosis, JNCL = juvenile neuronal ceroid 
lipofuscinosis. 
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1.3.1. Epidemiology in Finland 
 
In Finland, up to June 2001, altogether 411 patients with NCL have been 
diagnosed. This includes 163 patients with CLN1, 188 patients with CLN3, 
26 patients with CLN8, 28 patients with CLN5, 5 patients with CLN2, and 1 
patient with CLN4. No patients with congenital NCL, CLN6 or CLN7 have 
been diagnosed. From the incidence rates, it appears that two or three new 
patients with INCL and JNCL are born every year, whereas patients with 
LINCL are diagnosed more seldom. 
 
1.4. Neuropathological findings 
 
In every NCL type, there is a uniform accumulation of intralysosomal 
autofluorescent lipopigments. These pigments have been found to consist 
mainly of the saposins (SAPs) (Tyynelä et al. 1993) or subunit c of 
mitochondrial ATP synthase (SCMAS) (Hall et al. 1991, Palmer et al. 
1992). Saposins are found in the congenital form of NCL and in INCL, 
whereas SCMAS is found in the other types. SCMAS is also known to 
accumulate in some other lysosomal diseases, including 
mucopolysaccharidosis, mucolipidosis and gangliosidosis.  
 
Ultrastructurally, the storage material is characterised by granular, 
curvilinear, rectilinear, or fingerprint patterns (Table 3). The accumulation 
of storage material results in ballooning of the neuronal perikarya, a 
phenomenon called the Schaffer-Spielmeyer process (Goebel 1995). In 
addition, there is loss of nerve cells, the degree of loss depending on the 
NCL subtype and on the age of the patient (Goebel 1995). 
 
The cells most easily obtained for microscopic examinations are the 
lymphocytes in the peripheral blood. Vacuolisation of the lymphocytes, 
observable with the light microscope, can be used as a screening method for 
JNCL. In the other types of NCL, vacuolisation is not seen with the light 
microscope, and inclusions must be searched for with the 
electronmicroscope (EM). However, inclusions are present only in a 
minority of the lymphocytes, which makes the EM an unreliable diagnostic 
tool, when using peripheral lymphocytes. Thus, if it is necessary to confirm 
the diagnosis with EM, either a skin biopsy including the cells of the sweat 
glands (Carpenter et al. 1977) or a rectal biopsy including the submucosal 
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ganglion cells, is preferred to peripheral blood lymphocytes (Rapola et al. 
1984). 
 
_____________________________________________________________ 
 
Table 3. Histopathological data on the different types of NCL  
_____________________________________________________________                           
 
Gene  Ultrastructure      Main storage 
  (patterns)        material 
___________________________________________________________________ 
 
(CNCL) GRODs       SAPs 
CLN1  GRODs       SAPs  
CLN2  Curvilinear       SCMAS 
CLN3  Fingerprint / Curvilinear / Rectilinear   SCMAS 
CLN4  Fingerprint / Curvilinear / GRODs   SCMAS 
CLN5  Fingerprint / Curvilinear / Rectilinear   SCMAS 
CLN6  Fingerprint / Curvilinear / Rectilinear   SCMAS 
CLN7  Fingerprint / Curvilinear / Rectilinear   ? 
CLN8  Curvilinear       SCMAS  
_____________________________________________________________ 
 
CNCL = congenital neuronal ceroid lipofuscinosis, GRODs = granular osmiophilic 
deposits,  SAPs = saposins A and D, SCMAS = subunit c of mitochondrial  ATP synthase. 
? = not known. 
 
 
1.5. Neurophysiological findings 
 
Before genetic testing was available, neurophysiological examinations were 
used to confirm the diagnosis of NCL. Today, the various 
neurophysiological methods are still valuable for confirmation of the disease 
in some atypical cases and in genotype-phenotype correlation.  
 
Electroencephalogram (EEG) 
 
In NCL diseases in general, there is a progressive slowing of the 
background activity in the EEG (Sainio 1997). In addition, both generalised 
and focal paroxysmal activity may be noticed.  
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In INCL, the first abnormalities noted in the EEG are lack of attenuation to 
eye opening, and disappearance of sleep spindles (Vanhanen 1997). 
Thereafter, attenuation of the EEG gradually increases, leading to a totally 
inactive EEG by the age of 2-3 years.  
 
In LINCL, the specific EEG features include posterior spikes to low-
frequency photic stimulation. These are noticed around the age of 3 years in 
cLINCL and between the ages of 7 and 11 years in vLINCLFinn 
(Pampiglione and Harden 1977, Santavuori et al. 1991). 
 
In JNCL, the EEG reveals runs of high-amplitude delta waves, intermingled 
with spikes and/or sharp waves (Lagenstein et al. 1978, Westmoreland et al. 
1979). Until the age of 9, the EEG is usually normal. Thereafter, a 
progressive background abnormality and an increase in paroxysmal activity 
are seen (Larsen et al. 2001) When using quantitative analysis, the EEGs 
were found to be significantly slower than those of age-matched controls. 
The peak and mean frequencies and the fast/slow ratio were significantly 
lower, and the total power and the percentage of theta significantly higher 
than those of the controls. With age, the increase in the fast/slow ratio was 
significantly lower in the patients than in the controls.  
 
Electroretinogram (ERG) and visual evoked potential (VEP) 
 
Retinal degeneration leads to attenuation of ERG amplitude in all the main 
childhood-onset NCL types. Furthermore, in both INCL and JNCL, there is  
progressive attenuation of the potential of VEP and prolongation of the 
latency in VEP. In patients with LINCL, however, giant VEPs are seen. 
 
In patients with INCL, the ERG ceases to be recordable between the ages of 
1 and 4 years (Harden et al. 1973, Bischof et al. 1983). The visual evoked 
potentials (VEPs) are extinguished after the ages of 2 to 5 years (Harden et 
al. 1973, Bischof et al. 1983, Vanhanen et al. 1997).  
 
In patients with cLINCL, the ERG is extinguished at an early stage, but a 
giant VEP can be elicited by flash stimulation (Harden et al. 1973). This 
finding coincides with posterior spikes in the photic stimulation. The 
abnormal VEP may be seen until the late stages of the disease, when it 
diminishes. Similar kinds of ERG and VEP are found in patients with 
vLINCLFinn (Santavuori et al. 1999). 
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In patients with JNCL, the leading sign is visual failure. VEP and ERG are 
abolished early (Raitta & Santavuori 1981). Even prior to the onset of the 
disease, depressed VEPs and subnormal ERGs may be seen (Raitta and 
Santavuori 1981, Horiguchi and Miyake 1992).  
 
Somatosensory evoked potential (SEP) and somatosensory evoked 
magnetic fields (SEF) 
 
In INCL, the cortical SEP amplitudes are progressively attenuated. 
However, in patients with the variant and classic types of LINCL, a giant 
SEP is a typical finding (Santavuori et al. 1991, Schmitt et al. 1994). In 
JNCL, both normal (Harden & Pampiglione 1982) and enhanced (Schmitt et 
al. 1994) SEP findings have been described. In MEG recordings, the 
amplitude of the SEF is increased (Lauronen et al. 1997). 
 
1.6. Neuroimaging studies 
 
Non-invasive and rapid neuroimaging techniques are perhaps not diagnostic 
for the NCL disorders as such, but taken together with the clinical 
symptoms, they become highly diagnostic. Indeed, imaging methods can be 
considered as “windows to the brain”. Furthermore, they offer valuable 
information on the progress of the disease. Thus, they can also be used in 
monitoring the effects of any new therapies. 
 
Magnetic resonance imaging (MRI) 
 
In patients with INCL pathological MRI findings can be seen from the age 
of 7-11 months (Vanhanen et al. 1995). On T2-weighted images, the thalami 
are hypointense compared to the basal ganglia, and rims of high signal 
intensity may surround the lateral ventricles. Atrophy develops a few 
months later, cerebral atrophy outweighing cerebellar atrophy. 
 
In patients with cLINCL and vLINCL, prominent cerebellar atrophy is an 
early finding, followed by cerebral atrophy (Autti et al. 1997). High-signal 
rims in the white matter surround the ventricles (Autti et al. 1992). In 
addition, at least in the Finnish variant LINCL, the signal intensity of the 
thalami is lower than that of the basal ganglia (Autti et al. 1992). 
 
In patients with JNCL, MRI is usually normal in the early stages of the 
disease (Autti et al. 1996). Cerebral and later also cerebellar atrophy may be 
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seen after the age of 14 years. The signal intensity of the white matter is 
increased, especially in the periventricular area. However, these changes are 
not so pronounced as in INCL and LINCL. Slightly lowered signal 
intensities of the thalami may be seen after the age of 11 years. 
 
Spectroscopy 
 
In patients with INCL, there is almost complete loss of N-acetylaspartate, 
signifying a loss of neurons. Creatine and choline-containing compounds 
are markedly decreased as a sign of reduced glial membrane turnover. 
Myoinositol and lactate are elevated (Brockmann et al. 1996).  
 
In patients with LINCL, N-acetylaspartate is decreased, whereas lactate, 
myoinositol, creatine and choline-containing compounds are increased 
(Brockmann et al. 1996, Seitz et al. 1998).  
 
In patients with JNCL the spectroscopy is normal at the early stage, but later 
on, reduced N-acetylaspartate and creatine are noticed in the grey matter 
(Brockmann et al. 1996). 
 
Single photon emission computerised tomography (SPECT) 
 
In INCL non-specific cortical hypoperfusion was noticed in brain perfusion 
SPECT at an early stage, whereas reduction in cerebellar perfusion appeared 
later (Liewendahl et al. 1997). Perfusion of the basal ganglia and thalami 
was relatively well preserved up to the terminal stage. Patients with 
vLINCLFinn had bilateral supra- and infratentorial hypoperfusion even at an 
early stage of the disease, and cerebellar hypoperfusion was a characteristic 
finding (Autti et al. 1992). In JNCL, on the other hand,  hypoperfusion was 
pronounced in the temporal lobes and mild in the parietal and occipital lobes 
as well as in the cerebellum (Launes et al. 1996). 
 
Positron emission tomography (PET) 
 
Using 2-deoxy-2[18F]fluoro-D-glucose (FDG) as a tracer for PET studies, 
age-dependent, progressive  hypometabolism was found in patients with 
JNCL (Philippart et al. 1994). The hypometabolism started in the calcarine 
area and spread rostrally to the entire cortex. However, the basal ganglia and 
brainstem were relatively spared, and the uptake of FDG in these areas was 
considered normal. 
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2. CLINICAL PICTURE IN JNCL 
 
 
2.1. Visual failure 
 
In JNCL, the first sign is almost invariably visual failure, noticed around the 
age of 4 to 7 years. Presumably retinal, cortical, and optic nerve 
degeneration all account for the declining vision. The loss of photoreceptors 
in the retina gradually spreads from the retinal periphery towards the macula 
(Goebel 1995). In the ophthalmological examination the typical findings 
include macular degeneration, optic atrophy, thinning of the vessels, and 
accumulation of pigment in the peripheral retina (Spalton et al. 1980). These 
specific findings are suggestive of the diagnosis of an NCL disorder.  
 
At the start of the visual failure, paradoxically, patients often seem to use 
their peripheral retina, giving an impression of “overlooking” with their 
heads turned to the other side (Hofman et al. 1999). The rapid decline of the 
vision usually leads to blindness within 2 to 6 years. However, light 
perception may be preserved for years. Moreover, even after the patients are 
blind, vivid visual hallucinations may sometimes occur (Boustany 1992). 
 
2.2. Mental decline 
 
The most difficult symptom for parents with JNCL children to accept is 
probably dementia (Boustany and Filipek 1993). A slight mental decline 
sets in already at an early stage of the disease (Lou and Kristensen 1973, 
Santavuori and Moren 1977, Kristiansen 1987). In the study by Lou and 
Kristensen, involving 28 patients aged 6–28 years, only one had an IQ of 
over 90. In the early school years, gradual psychomotor deterioration 
becomes evident, and the children have difficulties in following the normal 
educational program, partly also because of their visual failure.  
 
Lou and Kristensen (1973) found a low digit memory span in the majority 
of their patients and assumed that digit memory span is one of the first 
functions to be impaired in JNCL. However, they found no marked 
tendency for the digit memory span to decline with age. Kristiansen (1987), 
on the other hand, found a low and declining digit memory span at an early 
stage of the disease. 
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2.3. Epilepsy 
 
The predominant type of seizure is a generalised tonic-clonic seizure, but 
complex partial seizures are also noticed (Hofman et al. 1999). Absence 
seizures have not been observed. Furthermore, in EEG recordings, the 
typical 3 Hz spike and slow wave discharges of absences have not been 
found. The epilepsy in JNCL is regarded as myoclonic (Berkovic 1986), and 
the enhanced somatosensory evoked magnetic fields (Lauronen et al. 1997) 
support the assumption that these patients have a myoclonic component, 
although myoclonia is not always observed.  
 
With age, the seizures tend to increase in frequency and in severity and, 
especially at puberty, an increase in the seizure frequency may be observed 
(Boustany and Filipek 1993). However, there is great individual variability, 
and in patients with early onset and poor seizure control, the clinical course 
tends to be malignant (Boustany 1992, Kohlschutter et al. 1988). 
 
2.4. Extrapyramidal symptoms 
 
Parkinsonian signs are noted in about half the patients between the ages of 
12 and 14 years (Järvelä et al. 1997). In the rest, these symptoms occur later. 
The most common extrapyramidal symptoms in patients with JNCL include 
impaired balance, rigidity, hypokinesia, stooped posture and shuffling gait 
(Hofman et al. 1999).  
 
In a PET study of nine patients with JNCL, a correlation was found between 
extrapyramidal symptoms and a decline in [18F]fluorodopa uptake in the 
putamen (Ruottinen et al. 1997), indicating nigrostriatal dysfunction. 
 
2.5. Hormonal changes in girls with JNCL 
 
Girls with JNCL have an early menarche (Lou and Kristensen 1973, Åberg 
et al., submitted). Irregular cycles are common, and in girls with regular 
cycles the cycle length is short. Acne, obesity, and hirsutism, reflecting 
hyperandrogenism, are often seen. These may be due to the use of valproate 
(VPA), previously found to cause hyperandrogenism and polycystic ovaries 
(PCO), especially in young women (Isojärvi et al. 1993, Vainionpää et al. 
1999). Indeed, 80% of the JNCL patients with hyperandrogenism had 
present or previous therapy with VPA. On the other hand, PCO were found 
in only 2 out of 8 girls with spontaneous cycles, a frequency within the 
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normal range at which PCO are found in young women (Michelmore et al. 
1999). However, both girls with PCO had a full-blown polycystic ovary 
syndrome (PCOS), whereas usually only a minority of patients with PCO 
manifest this syndrome (Knochenhauer et al. 1998, Michelmore et al. 1999). 
 
2.6. Psychiatric disturbances and sleep disturbances 
 
In patients with JNCL, severe psychiatric symptoms are common (Hofman 
1999, Santavuori et al. 1993, Boustany 1992). These include anxiety, 
depression, and psychotic symptoms, and they greatly influence the well-
being of the patients and their families.  
 
During the first few years after the diagnosis, the behavioural symptoms 
prevail. Depression is sometimes interpreted as a normal reaction to the 
deteriorating condition, but it may also assume a more serious connotation 
(Boustany and Filipek 1993). Depression may be manifested not only as 
sorrow, but also as unrest, aggressive outbursts, autoaggressive behaviour, 
and anxiety (Santavuori et al. 1993). 
 
Sleep problems are common in patients with JNCL, and may have a 
considerable effect on the well-being of the patients and their families. Sleep 
disorders, including settling problems, nocturnal awakenings, and 
nightmares had occurred in more than half of the patients, becoming evident 
at a mean age of 11 years (Santavuori et al. 1993). These problems seemed 
to increase during psychotic and restless periods as well as during periods of 
poor seizure control and tension (Santavuori et al. 1993, Kirveskari 2000). 
 
In the later stages of the disease, psychotic symptoms become more 
common, and may be observed in more than 75% of the patients (Sørensen 
and Parnas 1979). These psychotic incidents may manifest as hallucinations 
or delusions, characterised by strong anxiety, motor restlessness, or 
agitation. The visual hallucinations are often frightening, although 
sometimes these may also be experienced as colourful and harmless 
patterns. 
 
2.7. Other symptoms 
 
Although, in JNCL, the symptoms mainly reflect the disease of the CNS, 
cardiac problems are also seen. Electrocardiographic abnormalities are 
frequent in the later stages of the disease, and include ST depression and 
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negative T waves (Hofman et al. 1999, Hofman et al. 2001). In addition, 
arrhythmias are common (Hofman et al. 2001), and in some patients these 
have led to installation of a pace-maker (Santavuori, personal 
communication). In the morphological evaluation, prominent involvement 
of the heart is seen; storage material is found not only in the myocardium, 
but also in the valvules and the conduction system. Storage is associated 
with hypertrophy, dilatation of the ventricles, degenerative myocardial 
changes, interstitial fibrosis and fatty replacement (Hofman et al. 2001). 
 
 
3. DIAGNOSTICS OF JNCL 
 
The first sign of JNCL is visual impairment, appearing between the ages of 
4 and 8 years. This usually leads to an ophthalmological examination, at 
which typical findings are made (chapter 2.1.). The ophthalmological 
findings, along with the age of the patient, are suggestive of JNCL. 
Furthermore, if vacuolated lymphocytes are seen with the light microscope, 
the diagnosis is even more likely. However, the diagnosis is usually 
confirmed by gene testing, which can be used even prenatally (Munroe et al. 
1996). This possibility may be offered to families with children already 
diagnosed with JNCL. 
 
If gene testing is not available, or if it appears negative, as in patients with a 
rare mutation on both chromosomes, electron microscopy of a biopsy 
sample is needed. In Finland, a rectal biopsy is preferred, whereas in some 
other countries, a skin biopsy is taken. Thus, if characteristic ultrastructure 
is seen in the ganglion cells of the submucosa of a rectal biopsy specimen or 
in the sweat glands of a skin biopsy specimen, the diagnosis is confirmed. 
 
 
4. TREATMENT OF JNCL 
 
 
Antiepileptic drugs 
 
The combination of partial and generalised seizures with a myoclonic 
component makes AED therapy in JNCL demanding. Previously, several 
AEDs, including phenytoin, carbamazepine, phenobarbitone, and 
ethosuximide, have been tried in patients with JNCL (Boustany and 
Kolodny 1989). However, in myoclonic epilepsies, phenytoin and 
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carbamazepine are contraindicated. In fact, phenytoin was found to be 
unfavourable in patients with JNCL (Viukari 1969). Furthermore, 
behavioural problems, including aggression and depression, which are 
frequent in patients with JNCL, contraindicate the use of phenobarbitone 
(Committee on Drugs 1985). Ethosuximide has not been used widely in 
JNCL, for the most common seizure types are generalised tonic-clonic 
seizures, and absences have not been observed. 
 
In earlier studies, VPA and CZP were considered favourable (Boustany and 
Kolodny 1989). However, the hormonal side effects associated with 
valproate (Isojärvi et al. 1993) may aggravate the problems in blind girls 
with JNCL, who have difficulties in moving around due to motor 
impairment.  
 
LTG has previously been found to be effective in both partial and 
generalised seizures (Besag et al. 1995), but in myoclonic epilepsies, the 
results have been contradictory (Wallace 1990, Gibbs et al. 1992, Timmings 
and Richens 1993, Schlumberger et al. 1994). LTG has also been well 
tolerated in children with severe developmental abnormalities, and may 
have resulted in improvements in concentration, learning, and behaviour, 
independently of seizure control (Hosking et al. 1993, Uvebrant and 
Bauziene 1994). 
 
Treatment of extrapyramidal signs 
 
Only one controlled study has been reported of the antiparkinsonian 
treatment on patients with JNCL (Zweije-Hofman et al. 1982). In this study, 
eight patients with JNCL were included, and these patients were divided 
into two groups of four patients, one group receiving antiparkinsonian drugs 
and the other receiving placebo on a double-blind basis. As antiparkinsonian 
drugs, levodopa, amantadine and orfenadrine were used for a period of 12-
16 weeks. After this, two new groups were randomly selected. Three 
patients did not complete the 1-year-long trial. As regards the rest, no effects 
of the treatment were found, but the duration of treatment was short and 
only four of the patients received levodopa. 
 
However, encouraging results were also reported on the antiparkinsonian 
treatment of patients with JNCL, although these results were gained in an 
uncontrolled, unsystematic fashion (Zeman 1970). 
 
  
 
28
 
Hormonal interventions 
 
In the 1960s, as the progress of the disease was observed to increase at the 
time of the puberty, and as there were difficulties in maintaining hygiene, 
oophorectomy was performed in some female patients with JNCL (Järvinen 
et al. 1996). As new hormonal therapies became available, it became 
possible to abolish menstruation, if this was considered necessary by the 
families. 
 
Psychotropic treatment 
 
Until recent years, the psychotropic drugs most commonly used in patients 
with JNCL were the conventional antipsychotics, such as levomepromazine, 
and benzodiazepines (Boustany 1992, Santavuori 1993). However, there is 
now an increasing tendency to use atypical antipsychotics and serotonin-
selective reuptake inhibitors even in children with intellectual disability 
(Santosh and Baird 1999). In a recent study on patients with JNCL, 
citalopram and new atypical antipsychotics were tried and found beneficial 
(Bäckman et al. 2001). 
 
Other drug treatment modalities  
 
Based on the theory suggesting that NCLs are due to a defect in lipid 
peroxidation, antioxidant treatment has been tried in  patients with JNCL, in 
the hope of preventing rapid deterioration (Santavuori et al. 1988). To date,  
however, no definite benefits of this therapy have been confirmed, but 
because of the favourable effect of the antioxidant treatment on the 
secondary impairment of peroxidation and apoptosis (Kieseier et al. 1997), 
therapy with antioxidants has been continued in most patients. 
 
As polyunsaturated fatty acids were observed to reverse the accumulation of 
storage material in cultured lymphoblasts from patients with JNCL (Bennett 
et al. 1994), they were tried in MND mice, but with disappointing results. 
Therefore, polyunsaturated fatty acids have not been tried in patients with 
JNCL or in any other patients with NCL either. 
 
In some lysosomal disorders, bone marrow transplantation has been 
successful (Kaye 1995). The idea is that the donor’s macrophages crossing 
the blood brain barrier would supply the deficient enzyme. However, unless 
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the infiltration is part of the natural clinical course, these macrophages will 
not supply adequate amounts of the deficient enzyme. Indeed, in a study on 
bone marrow transplantation on English setters, serving as an animal model 
for the disease, the results were not encouraging (Deeg et al. 1990). 
 
Bone marrow and stem cell transplantation have been tried, nevertheless, in 
several patients with INCL (Vanhanen et al. 1997, Lake et al. 1997) and in 
one patient with JNCL (Lake et al. 1997). In INCL, stem cell transplantation 
seemed initially to retard the progression of the disease, but no long-term 
benefit was observed (Lönnqvist et al., in press). In a patient with JNCL, 
even a temporary effect of the stem cell transplantation would be more 
difficult to evaluate, as this disease progresses more slowly. Furthermore, 
the defect in INCL being an intralysosomal protein and in JNCL a 
lysosomal transmembrane protein, the potential of a transplantation seems 
limited in JNCL. Thus, stem cell transplantation has not been tried in other 
patients with JNCL. Furthermore, transplantation should be performed at a 
very early stage of the disease, as considerable nerve cell damage has 
already taken place when the first signs appear.  
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AIMS OF THE PRESENT STUDY 
 
 
The two main goals of the present study were to define the clinical picture 
and to optimise the treatment of JNCL. To achieve the main goals, the study 
focused on the following aspects: 
  
1. To develop a neuropsychological test battery for patients with JNCL and 
to clarify the neuropsychological profile of the patients with JNCL. 
 
2. To characterise the type of epilepsy in patients with JNCL and to find 
determine the optimal antiepileptic drugs for use in these patients. 
 
3. To evaluate the mechanism underlying the motor impairment in JNCL 
and to test the effect of antiparkinsonian treatment on these patients. 
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MATERIALS AND METHODS 
 
 
1. PATIENTS 
 
Sixty of the 61 patients with JNCL alive in Finland during the years 1996-
2000 were included in the study. The characteristics of the patients and their 
medication are listed in Table 4. This table provides information as to the 
studies in which the patients were included. In all cases the diagnosis of 
JNCL, based on the clinical picture and electronmicroscopic findings on a 
rectal biopsy, had earlier been confirmed at the Hospital for Children and 
Adolescents, University of Helsinki. In addition, DNA testing was used to 
confirm the disease in all patients except one.  
 
The majority of the patients (n=40) were regularly followed-up at the 
Hospital for Children and Adolescents. In some cases, the patients were 
treated in local hospitals, but contact was kept by telephone or by visits to 
the local hospitals. 
 
As regards genotype, 48 patients were homozygous for the major mutation, 
a 1.02 kb deletion, 11 were compound heterozygotes, and in one case the 
genotype was not tested. All the patients were visually impaired, and most 
of them also had varying degrees of neurological impairment. Most patients 
were on antiepileptic medication, while some also had psychotropic 
medication, antiparkinsonian treatment and/or hormonal therapy. 
 
The studies were accepted by the Ethical Committee of the Hospital for 
Children and Adolescents, University of Helsinki, and all the patients were 
examined with the approval of their parents. 
 
 
2. NEUROPSYCHOLOGICAL TEST BATTERY  
 
Fourteen patients diagnosed at the Hospital for Children and Adolescents 
consecutively during the years 1988–1990  were included in the prospective 
neuropsychological follow-up. They were five boys and nine girls. Their 
ages at confirmation of the diagnosis ranged from 5 to 10 years (mean 8.2 
years). The first neuropsychological examination was carried out within a 
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Table 4. Characteristics of the patients and participation in the 
different studies.  
 
No Year 
of 
birth 
Sex Geno-
type* 
Study 
I** 
Study 
II** 
Study III  
§ 
Study 
IV** 
Study V   
‡ 
Psycho-
tropic 
drugs £ 
1. 1982 Male 1  X VPA, LTG X Levodopa RIS 
2. 1981 Female 1  X LTG X Levodopa RIS, CIP 
3. 1979 Male 1 X  VPA X Levodopa None 
4. 1981 Male 2  X LTG, CZP X Selegiline None 
5. 1981 Female 2 X X LTG, CZP  Control None 
6. 1983 Female 2 X X LTG, CZP  Control CIP 
7. 1990 Male 2   No AEDs   None 
8. 1982 Female 1  X LTG, CZP X Control RIS, CIP 
9. 1981 Male 1   VPA   None 
10. 1975 Female 1   VPA   None 
11. 1981 Male 1 X X LTG, CZP X Levodopa None 
12. 1979 Female 1   Polytherapy   None 
13. 1981 Female 1 X  VPA, LTG X Levodopa CIP 
14. 1979 Female 1  X LTG   None 
15. 1990 Female 1   LTG   None 
16. 1983 Female 1 X X Polytherapy X  RIS, CIP 
17. 1978 Male 1   VPA   RIS, ALP 
18. 1984 Male ?  X LTG, CZP X Levodopa None 
19. 1989 Female 1   LTG   None 
20. 1974 Male 1   VPA   LEV, PER 
21. 1979 Male 1 X  VPA X Levodopa None 
22. 1982 Male 1   No AEDs   None 
23. 1966 Male 2  X LTG X  None 
24. 1970 Female 1   VPA, CZP   None 
25. 1965 Male 1   VPA, CZP   None 
26. 1982 Female 2 X X LTG, CZP  Control RIS, CIP 
27. 1982 Female 2 X X LTG, CZP X Control None 
28. 1988 Male 1  X LTG   None 
29. 1991 Female 1   VPA, LTG   None 
30. 1993 Female 1   No AEDs   None 
31. 1984 Male 1 X X LTG X Selegiline None 
32. 1986 Male 1   VPA   None 
33. 1977 Male 2   VPA, CZP   None 
34. 1986 Female 1  X LTG X  None 
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Table 4. (continued) 
 
No Year 
of 
birth 
Sex Geno-
type * 
Study 
I** 
Study 
II** 
Study III § Study 
IV** 
Study V  
‡ 
Psycho-
tropic 
drugs £ 
35. 1983 Female 1 X X LTG, CZP  Levodopa None 
36. 1989 Female 1   LTG   None 
37. 1979 Female 1 X  Polytherapy  Levodopa None 
38. 1981 Male 1  X VPA, LTG   ALP, MEL 
39. 1986 Female 1   LTG X Selegiline None 
40. 1987 Male 1  X LTG X Selegiline None 
41. 1990 Male 1   No AEDs   None 
42. 1990 Male 1   No AEDs   None 
43. 1988 Female 1   No AEDs   None 
44. 1986 Female 1  X LTG X Selegiline None 
45. 1974 Male 1   VPA, CZP  Levodopa None 
46. 1978 Male 1  X Polytherapy   None 
47. 1979 Female 1  X VPA, LTG   None 
48. 1974 Female 1  X VPA, LTG   LEV 
49. 1978 Male 1   VPA   None 
50. 1975 Male 1   VPA, CZP   None 
51. 1987 Female 1  X LTG, CZP  Selegiline None 
52. 1971 Male 2   VPA, CZP   OXA 
53. 1977 Male 1   VPA, CZP   None 
54. 1990 Male 1   LTG   None 
55. 1976 Male 1   VPA, CZP   None 
56. 1990 Male 2   No AEDs   None 
57. 1989 Male 2   No AEDs   None 
58. 1976 Male 1  X VPA, LTG   None 
59. 1973 Male 1  X VPA, LTG   None 
60. 1978 Female 1 X X LTG, CZP   LEV, OXA 
 
The medication of the patients at the end of 1998. It is stressed that there were continuous 
dose adjustments as well as changes of the drugs used. 
* Genotype 1 = heterozygous and  2 = homozygous for the major  mutation. ? = not known. 
** Patients included in studies I, II, and IV. 
§ Patients included in study III and their antiepileptic drugs (AEDs); VPA = Valproate, 
LTG = Lamotrigine, CZP = Clonazepam. 
‡ The treatment of the patients included in study V. 
£ Psychotropic drugs: RIS = Risperidone, CIP = Citalopram, ALP = Alprazolam, LEV = 
Levomepromazine, PER = Perazine, OXA = Oxazepam, MEL = Melperone. 
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year after the confirmation of the diagnosis of JNCL, and subsequently once 
a year during the 5-year-long study.  
 
The neuropsychological test battery was specially developed for patients 
with JNCL. The battery was adapted from Luria’s neuropsychological test 
for children (Christensen 1974) and from NEPSY (Korkman 1988) and was 
modified for the visually handicapped. A verbal WISC-R was included in 
the test battery (Wechsler 1974). The battery consisted of 12 items, most of 
them with sub-items (Table 5). All instructions for the patients were given 
in a verbal or tactual manner. 
 
Orientation was evaluated to persons, time, and place. Orientation to 
persons was studied by orientation to name, age, birth date, mother’s name 
and father’s name. Orientation to time was studied by orientation to 
weekday, day of the month, month, year, time of day and season. 
Orientation to place was evaluated by recognition of the home town, 
address, school and class. 
 
Attention was considered normal if the child was able to concentrate for 45 
minutes and impaired if several breaks were needed. To test dominance and 
motor functions, the motor speed of the hands was evaluated in a tapping 
test by recording the number of taps of the thumb with the index finger 
during 10 seconds. In acoustic rhythms, the repetition of rhythms was 
studied; six different series of rhythmic taps were used. 
 
As regards arithmetic, comprehension of number structure was evaluated 
from the ability to understand numerical differences, i.e. which of two 
numbers was the larger (eight pairs of numbers). In arithmetical operations, 
basic processes of calculation were studied. 
 
As regards mnestic processes, short-term memory was evaluated from how 
many numbers the patient could recall. To test tactile memory, the patient 
was given several objects and, when one of these was removed, was asked 
to name it. In stereognosis, the patient was asked to name objects placed on 
the palm of the hand. In spatial orientation, the patient reproduced figures 
formed from matches. In addition, the patient was asked to organise objects 
in a doll’s house according to instructions such as “put the chair in front of 
the table” or “put the dog under the table”. Both stereognosis and spatial 
orientation were studied with vision totally excluded.  
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_____________________________________________________________ 
 
Table 5. The neuropsychological test battery for patients with JNCL 
_____________________________________________________________ 
  
1. General orientation 
Person (maximum points 6) 
Time (maximum points 6) 
Place (maximum points 4) 
2. Attention (qualitative) 
3. Dominance and motor functions 
Preference (right / left)  
Motor speed of the right hand (tapping test 10 seconds) 
Motor speed of the left hand (tapping test 10 seconds) 
Dexterity (qualitative) 
Oral praxis (qualitative) 
4. Verbal IQ (WISC-R) 
Information (1-19 standard points) 
Similarities (1-19 standard points) 
Arithmetic (1-19 standard points) 
Comprehension (1-19 standard points) 
Digit memory span (1-19 standard points) 
5. Speech (qualitative) 
Expressive speech (including articulation and fluency) 
Receptive speech 
Comprehension 
6. Acoustic rhythms (maximum points 6) 
7. Reading and writing skills (qualitative) 
Using vision / Braille 
8. Arithmetic 
Comprehension of number structure (maximum points 8) 
Arithmetical operations (qualitative) 
Arithmetic (WISC-R)  
9. Mnestic processes 
Short-term memory (usually 5 - 6) 
Tactile memory (maximum points 6) 
Repeating a story (maximum points 8) 
10. Stereognosis (qualitative) 
11. Spatial orientation (maximum points 15) 
12. Quality of performances (qualitative) 
_____________________________________________________________ 
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Two of the patients were not included in the analysis of changes in IQ; these 
patients were excluded as outliers. One was a female, homozygous for the 
major mutation, who was already mentally retarded when first seen at the 
age of 10. The other was a compound heterozygous male with an increase in 
IQ during the study period . 
 
Fifteen healthy children served as control subjects in the tapping test. 
Otherwise, no control patients were used, since both the WISC-R and the 
NEPSY have previously been standardised in healthy children.  
 
 
3. DATA COLLECTION ON EPILEPSY AND AEDs  
 
Sixty patients were included in this retrospective and cross-sectional study. 
Data on seizures and AEDs were obtained from the medical records, by 
interviewing parents, and by contacting the personnel of the local hospitals 
or institutions where some of the patients were followed up. 
 
The age at onset of epilepsy and the seizure types were recorded. Seizures 
were classified according to the Proposal for revised clinical and 
electroencephalographic classification of the International League Against 
Epilepsy (1981). The seizure frequencies were taken as the total numbers of 
seizures during one year, and were divided into three categories; none, one 
to six seizures, and seven or more seizures a year. Even the mean duration 
of the seizures was checked. Seizure control was defined as good in the 
absence of seizures, and satisfactory if the frequency was six seizures or 
fewer a year. Poor seizure control was defined as a seizure frequency of 
more than six a year. As regards seizure duration, seizure control was 
defined as poor if there were any prolonged seizures (more than 20 minutes) 
during the study year.  
 
AED treatment had been initiated as monotherapy according to the common 
practice, and the dose was titrated upward until a seizure-free condition was 
reached or the seizures decreased. If there were severe side effects, an 
alternative AED was tried. However, if seizure control was insufficient 
despite the use of the maximal dose tolerated, combination therapy was 
initiated. In cases of refractory epilepsy, polytherapy was used. 
 
The effect of the first AED used was determined retrospectively. The 
seizure frequencies at baseline (2 months) and after 1 year were compared; a 
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decrease in seizure frequency of over 50% was denoted as a decrease in the 
seizure frequency. In addition, the severity of the seizures and the general 
well-being of patients on LTG therapy (n=28) were compared. A decrease 
of over 50% in the length of the seizure and/or the post-ictal phase was 
denoted as a decrease in the severity of the seizures. A change in well-being 
was based on the general agreement of both doctors and parents. An 
increase in well-being included at least one of the following items: 
improvement in the quality of sleep with fewer settling problems and 
awakenings, in attention, and in daytime activity, and a decrease in 
irritation. 
 
The AED treatment of patients during the study year of 1998 was recorded 
and the patients were grouped on the basis of this treatment. For each group, 
the mean seizure frequency and the mean age of the patients were 
calculated, and the percentages of patients with good, satisfactory and poor 
seizure control were determined. The daily dosage of AEDs and the serum 
concentrations of VPA were checked.  
 
The AEDs used before the study year were studied as well. The side effects 
of these AEDs and the reasons for any withdrawal were clarified. In 
addition, any beneficial effects of these drugs, apart from seizure control, 
were assessed. 
 
 
4. EVALUATION OF EXTRAPYRAMIDAL SYMPTOMS  
 
A ß-CIT-SPECT study was performed to assess the role of the dopamine 
transporters (DATs) and possible advantages of the dopaminergic drugs on 
the extrapyramidal symptoms in JNCL. Patients followed up in the Hospital 
for Children and Adolescents, 10 years of age or older, and with no previous 
antiparkinsonian treatment were invited. Four of the patients refused and 17 
signed an informed consent. The mean age of the patients included was 15 
years (range 10–31).  
 
For clinical evaluation of the extrapyramidal signs, the motor part of the 
Unified Parkinson´s Disease Rating Scale (Fahn et al. 1987) was applied. 
With this method, the more severe the patient’s symptoms, the higher is the 
score (Table 6). Scoring was performed systematically by the same person 
(L.Å.). 
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_____________________________________________________________ 
 
Table 6. Motor part of the Unified Parkinson’s Disease Rating Scale 
(UPDRS) as given by Fahn et al. 1986. 
___________________________________________________________________ 
 
1. Speech 
0 = Normal. 
1 = Slight loss of expression, diction and / or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
2. Facial expression 
0 = Normal. 
1 = Minimal hypomimia, could be normal “Poker Face”. 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial  expression; 
lips parted ¼ inch or more. 
3. Tremor at rest 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only 
intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
4. Action or postural tremor of hands 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
5. Rigidity [Judged on passive movement of major joints with patient relaxed in 
sitting position; ignore cogwheeling.] 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
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6. Finger taps [Patient taps thumb with index finger in rapid succession with 
widest amplitude possible, each hand separately.] 
0 = Normal. 
1 = Mild slowing and / or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in  
ongoing movement. 
4 = Can barely perform the task. 
7. Hand movements [Patient opens and closes hands in rapid succession with 
widest amplitude possible, each hand separately.] 
0 = Normal. 
1 = Mild slowing and / or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in ongoing movement.  
3 = Severely impaired. Definite and early fatiguing. Frequent hesitation in  
initiating movements or arrests in ongoing movement. 
4 = Can barely perform the task. 
8. Rapid alternating movements of hands [Pronation-supination movements 
of hands, vertically or horizontally, with as large an amplitude as possible, 
each hand separately.] 
0 = Normal. 
1 = Mild slowing and / or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in  
ongoing movement. 
4 = Can barely perform the task. 
9. Leg agility [Patient taps heel on ground in rapid succession, picking up 
entire leg. Amplitude should be about 3 inches.] 
0 = Normal. 
1 = Mild slowing and / or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional  
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in  
ongoing movement. 
4 = Can barely perform the task. 
10. Arising from chair [Patient attempts to arise from a straight-back wood or 
metal chair with arms folded across the chest.] 
0 = Normal. 
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1 = Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up 
without help. 
4 = Unable to arise without help. 
11. Posture 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to 
one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one  
side. 
4 = Marked flexion with extreme abnormality of posture. 
12. Gait 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening  
steps) or propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some  
festination, short steps or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
13. Postural stability [Response to sudden, strong posterior displacement 
produced by pull on shoulders while patient erect with eyes open and feet 
slightly apart. Patient is prepared, and can have had some practice runs.] 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
14. Body bradykinesia and hypokinesia [Combining slowness, hesitancy, 
decreased armswing, small amplitude, and poverty of movements in general.] 
0 = None. 
1 = Minimal slowness, giving movement a deliberate character; could be 
normal for some persons. Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely  
abnormal. Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
___________________________________________________________________ 
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For studying the density of DATs in the striatum, iodine-123-labelled 2β-
carbomethoxy-3β-(4-iodophenyl) tropane ([123I]β-CIT) was applied as a 
SPECT tracer. SPECT imaging was performed 24 hours after the injection.  
 
The SPECT images were evaluated visually and tracer accumulation was 
semiquantified from transverse slices as striatum-to-cerebellum activity 
ratios. Regions of interest (ROIs) were drawn manually with the help of 
magnetic resonance imaging (MRI), when available, and counts-per-pixel 
values were calculated for each ROI (Figure 1). Separate caudate-to-
cerebellum and putamen-to-cerebellum ratios were calculated. These ratios 
were compared with the clinical scores.  
 
 
Figure 1. Regions of interest (ROIs) in SPECT images 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tracer accumulation in SPECT images was semiquantified from transverse slices as 
striatum-to-cerebellum ratios. ROIs were drawn manually with the help of MRI (Pohjonen 
et al. 1996). Thereafter, counts per pixel were calculated for each ROI. 
 
 
Evaluation of the SPECT images and clinical scoring were performed 
blinded; clinical scoring was performed 1 day prior to SPECT imaging. 
Furthermore, the SPECT images were evaluated without information on the 
clinical scoring. 
 
The control group consisted of 16 subjects with normal β-CIT-SPECT study 
images and uptake ratios. The control patients were studied because of 
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dystonia or suspected parkinsonism. The mean age of this control group was 
43 years (range 14-56). For ethical reasons, age-matched controls were not 
available. 
 
 
5. MAGNETIC RESONANCE IMAGING 
 
All 14 patients participating in the neuropsychological test battery were 
examined with a 1.0 T MRI at the beginning of the study. After a mean 
follow-up period of 5 years, 11 patients were re-examined with either a 1.0 
or a 1.5 T MRI. After T1-weighted sagittal images, T2-weighted axial slices 
were obtained and the changes in atrophy and signal intensity were graded 
as previously described (Autti et al. 1996). 
 
Of the 17 patients participating in the SPECT study, 16 underwent a 1.5 T 
MRI 1 day prior to SPECT imaging. This MRI study was unlinked to the 
previous MRI study. One patient participating in the SPECT study, did not 
consent to undergo the MRI study. Axial T2-weighted and sagittal three-
dimensional T1-weighted images were obtained. The signal intensities of 
the striatum and thalami were measured from T2-weighted images as 
previously described (Autti et al. 1994) and the ratios between the signal 
intensities of the striatum and thalami were calculated. Cerebral and 
cerebellar atrophy were classified as mild, moderate, or severe (Autti et al. 
1996). As a control group for this MRI study, we used 16 age-matched 
healthy volunteers. 
 
 
6. THERAPY WITH ANTIPARKINSONIAN DRUGS 
 
After the ß-CIT-SPECT and MRI studies had been performed, the patients 
included in the study participated in an open study on the effects of the 
antiparkinsonian treatment. In addition, other patients, including those who 
did not give their permission for the SPECT study, were included in the 
study on the antiparkinsonian treatment. The mean age of the patients at the 
start of the study was 15 years (range 10–23). 
 
On the basis of the UPDRS score, treatment was initiated with either 
selegiline or levodopa. When the UPDRS score exceeded 10, therapy was 
initiated with selegiline (n=6). If the UPDRS score at the first evaluation 
was already 20 or more, treatment was initiated with levodopa (n=10). Five 
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patients with no parkinsonian therapy served as control subjects. These 
included patients with severe psychotic behaviour, contraindicating 
antiparkinsonian treatment. In addition, the control group included patients 
who did not give permission for drug treatment of parkinsonism. 
 
Selegiline was initiated  at 2.5 mg a day and after 2 weeks the dose was 
increased to 5 mg a day. The dose of selegiline was then increased in steps 
up to 7.5–10 mg a day. Levodopa was used in combination with carbidopa 
(100/25) to prevent peripheral decarboxylation. Levodopa therapy was 
initiated with a dose of 50 mg a day and the dose increased by 50 mg every 
2 weeks until a maintenance dose of 300-600 mg a day was achieved. 
 
Throughout the therapy, all the patients were followed up regularly for dose 
adjustments and for possible side effects. During visits to out-patient 
departments, patients were evaluated by a physician and a physiotherapist. 
Rehabilitation was kept constant during the follow-up. 
 
 
7. STATISTICAL METHODS 
 
In study II, Fisher’s exact test was used to examine the associations between 
seizure control and sex, genotype, and AED group. Regression analysis was 
used to test whether seizure frequency was correlated with age or with onset 
of epilepsy. 
 
In study IV, SPECT uptake ratios and MRI signal intensity ratios were 
compared in patients with extrapyramidal signs and in controls, using the 
Mann-Whitney U test. Multiple regression analysis was used to test for 
correlations between UPDRS, the striatal dopamine uptake ratios in SPECT, 
and the signal intensity ratios in MRI.  
 
In study V, the UPDRS score after 1 year was compared with the score at 
the start of the study, and the changes in the scores were studied in the 
different groups, using ANOVA. 
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RESULTS 
 
 
1. NEUROPSYCHOLOGICAL DECLINE 
 
In patients with JNCL, the mean cognitive performance at the time of the 
diagnosis was already at the level of low average. During the follow-up, the 
mean verbal IQ declined from 88 (low average) to 72 (borderline), but there 
was marked individual variation in the rate of decline. In the patients 
homozygous for the major mutation, the mean IQ decreased from 90 to 71, 
and in the heterozygotes from 85 to 73. The WISC-R profile was found to 
be characteristic, comprehension and digit memory span already being 
impaired at the onset (Figure 2). During the first 5 years after the diagnosis, 
declines were obvious in all the different sub-items. However, recognition 
of similarities seemed to be relatively well-preserved. 
 
Orientation to person and place usually remained stable during the study 
period, whereas orientation to time was well preserved only in half of the 
patients. Attention was not found to deteriorate. In the tapping test, motor 
speed began to decline at the age of approximately 10 years, whereas in the 
control patients increasing age correlated with improvements in this test. 
Dexterity was well preserved during the follow-up in half the patients, and 
oral praxis remained stable in all. 
 
Mild to moderate difficulties in expressive speech were observed in half the 
patients. Receptive speech remained normal in 12/14, and no decline was 
observed in the comprehension of speech. Normal age-dependent 
development of acoustic rhythms was found in 12/14 children. 
 
Eleven children with normal or only slightly subnormal IQs and some vision 
left at the onset of the study period learned to read. Nine of the children also 
learned to read Braille at the ages of 7–10 years. This ability was well 
preserved during the study period. With increasing age, reading and writing 
became more difficult to learn. 
 
Eight of the children could deal with figures above one thousand and had 
learned all the basic processes of calculation. They were able to use these 
skills throughout the study period. One child learned all the basic processes 
except for division. Four patients were only able to add and subtract, and 
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Figure 2. The mean WISC-R profiles of the 14 patients in the study at 
the onset, and after 3 and 5 years. 
 
 
 
The mean WISC-R profiles of the patients (n = 14), showing the mean standard score for 
each sub-item at the onset, after 3 years, and after 5 years of follow-up. 
 
 
one patient could only add small figures. Learned abilities were usually well 
preserved, but mastering new processes was increasingly  difficult.  
 
Short-term memory was impaired in all the patients from the beginning, but 
remained fairly stable throughout the study period. Individual variation was 
limited. Tactile memory and stereognosis remained normal in all the 
patients throughout the study period. In the logical repetition of a story, the 
mean score decreased from 7.3 to 6.8 (out of a maximum of 8). Stereognosis 
was found to be normal in all the patients throughout the study period. 
 
On comparing the neuropsychological performance of patients with 
different genotypes, no differences were found in the IQs or in the rate of 
the decline in the IQ. Spatial orientation was found to be impaired only in 
patients homozygous for the major mutation. Otherwise, the 
neuropsychological profiles in the different genotypes were similar. 
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2. EPILEPSY AND ANTIEPILEPTIC DRUG THERAPY 
 
The mean age when the first epileptic seizure occurred was 10.0 years 
(range 5-16). As regards seizure type, 14% of the patients had complex 
partial seizures, 18% had partial seizures with secondary generalisation, and 
52% had generalised tonic-clonic seizures. The remaining 16% had 
combinations of two different types of seizure: generalised seizures 
combined either with complex partial seizures or with myoclonic seizures. 
Myoclonic seizures were observed mostly in the final stages of the disease. 
 
Fifty of the 60 patients with JNCL had epilepsy at the time of the study and, 
of these 50 patients, 11 were seizure-free. Thirty-nine patients had seizures, 
the median frequency being four seizures a year (range 0-120). The duration 
of the seizures ranged from a few seconds to 20 minutes (median 2 
minutes). In 72% of the patients with epilepsy, seizure control was good or 
satisfactory. Neither the present seizure frequency nor the seizure control 
measure correlated with the patient’s age or with the age at onset of 
epilepsy. 
 
In most cases, the indication for AED therapy was seizures. In seven cases, 
however, AED treatment was first initiated because of irritation and/or sleep 
disturbances, such as settling problems and frequent awakenins. As the first 
AEDs used, VPA, LTG, and felbamate seemed equally effective, and 
resulted in a 50% decrease in seizure frequency in 80% of the patients. 
Phenobarbitone, on the other hand, resulted in a 50% decrease in seizure 
frequency in only 33% of the patients. 
 
During the follow-up year, monotherapy with VPA or LTG was used in 21 
patients, combination therapy in 27, and polytherapy in four patients. 
Seizure control in the groups with different AEDs or AED combinations 
differed significantly, the percentage of patients with satisfactory seizure 
control ranging from 25% to 100% (Figure 3). Optimal seizure control was 
found in patients on LTG monotherapy or LTG-CZP combination therapy. 
Of these patients, 100% and 91%, respectively, had satisfactory seizure 
control. On the other hand, 71% of the patients in VPA monotherapy and 
63% of the patients with a combination therapy of VPA and CZP had 
satisfactory seizure control. However, only 38% of the patients on a VPA-
LTG combination had satisfactory seizure control. In the polytherapy group, 
only 25% of the patients had satisfactory seizure control. 
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Figure 3. Groups with different AED therapies during the follow-up year 
and the percentage of patients in each group with good, satisfactory and 
poor seizure control. 
 
 
AED VPA LTG VPA- 
LTG 
VPA-
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Mean age of the 
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19 14      18 25 16 18 17 
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10.7  
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(63.5) 
14.2  
(4) 
Satisfactory 
seizure control 
71% 100% 38% 63% 91% 25% 72% 
 
 
The seizure control in the different AED groups differed significantly. All patients on 
lamotrigine monotherapy had satisfactory seizure control (0–6 seizures a year). However, 
the mean age in this group was low. AED = Antiepileptic drug, VPA = Valproate, LTG = 
Lamotrigine, CZP = Clonazepam, Poly = Polytherapy. 
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AED treatment was initiated during the follow-up year at a mean age of 8.4 
years (range 8–9). In all these cases, seizures indicated AED therapy, which 
resulted in a decrease (>50%) in seizure frequency in all. Additional AEDs 
(combination therapy) were initiated at a mean age of 15.6 years (range 7–
19), because of increasing seizure frequency. This led to a decrease in 
seizure frequency in all these patients. 
 
As regards the effects of LTG, initiated either as the first or as an additional 
AED, the seizure frequency decreased in 45% of the patients. The severity 
of the seizures decreased in 41%. During the follow-up, LTG was continued 
as monotherapy in 68% of the patients. In the remaining patients, because of 
inadequate seizure control, clonazepam was added to LTG after a mean 
period of 2.4 years (range 1.5–3.2). 
 
The most common side effects of the AEDs currently used were fatigue, 
weight gain, nausea and vomiting, and dizziness. These side effects were 
often transient, and disappeared after dose adjustments or spontaneously. In 
25% of the patients in whom AED treatment was used, however, side 
effects led to discontinuation of these medicaments. In VPA therapy, side 
effects such as hyperandrogenism, thrombocytopenia, or nausea and 
vomiting resulted in withdrawal in 20% of the patients. As regards LTG, 
there were no withdrawals because of side effects. In patients on CZP 
therapy, aggression led to discontinuation in 16% of the patients. PB was 
discontinued in 80% of the patients because of fatigue. 
 
Prior to the follow-up year, felbamate had been used in four patients for a 
short time, but was discontinued because of recognition of the risk of 
serious side effects. Vigabatrin was administered to three patients, but was 
withdrawn because of headache, depression, and lack of effect on seizures. 
Furthermore, oxcarbazepine was tried in one patient, but was discontinued 
because of increasing seizure frequency. 
 
Prior to and during the follow-up year, positive effects of AEDs, other than 
improved seizure control, were noticed. With the initiation of LTG, an 
increase in well-being, defined by a decrease in irritation and aggression or 
an increase in attention, activity, or quality of sleep, was noticed in 60% of 
the patients. With the initiation of VPA, an increase in well-being was 
observed in 15% of the patients. 
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3. EXTRAPYRAMIDAL SIGNS AND ß-CIT-SPECT  
 
The first extrapyramidal signs were noticed at the age of 10 years. At the 
beginning, these manifested as impaired balance, mild slowing or reduction 
of the amplitude of hand movements, and rigidity of the upper arms when 
activated by contralateral arm movements. However, at this age, the 
symptoms were mild and therefore usually not noticeable in everyday life. 
 
In patients with parkinsonian symptoms, reduced striatal uptake of ß-CIT 
was found in SPECT. The mean striatum-to-cerebellum ß-CIT uptake ratio 
was significantly lower in the patients than in the controls (3.1 + 0.6 vs. 6.8 
+ 1.0; p < 0.001). In one patient with no extrapyramidal signs, the SPECT 
image did not show abnormalities and the striatum-to-cerebellum ratio was 
above the lower reference limit of 4.85; in all the other patients the striatum-
to-cerebellum ratio was below the mean -2 SD of the control values. The 
decrease was relatively greater in the putamen than in the caudate. When the 
uptake ratios were compared with the clinical scores, a negative correlation 
was found; the smaller the ratio, the more severe the clinical symptoms 
(Figure 4). 
 
Figure 4. Negative correlation (R = -0.66, p < 0.004) between the ß-CIT 
uptake ratio in SPECT and  the clinical score as measured with the UPDRS 
(Unified Parkinson’s Disease Rating Scale). 
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4. MAGNETIC RESONANCE IMAGING (MRI) 
 
In the prospective neuropsychological follow-up, MRI was performed at the 
onset and after 5 years (Figure 5). At the onset, only two patients had 
abnormally high signal intensities in the periventricular white matter. After 
5 years, the MRI was abnormal in most patients. In addition to the changes 
in signal intensity, atrophic changes were also found (Study I, table 3). 
However, these MRI findings were not found to correlate with the severity 
of the clinical symptoms. 
 
 
Figure 5. Magnetic resonance images (T2-weighted axial slices) of a patient 
at the onset of the study and after 5 years. 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
    
On the left hand side, MRI image of the 8-year-old patient is considered normal. On the 
right hand side, the image of the same patient at the age of 13 years shows mild to moderate 
cerebral atrophy. In addition, the thalami appear hypointense compared to basal ganglia. 
 
In the study on extrapyramidal signs, MRI was performed 1 day prior to 
SPECT imaging. The mean striatum-to-thalamus signal intensity ratios in 
patients and controls differed significantly (1.14 + 0.02 vs. 1.08 + 0.02; p < 
0.001). However, the caudate-to-putamen ratios in patients and controls did 
not differ. There was a positive correlation between the clinical scoring and 
the MRI ratios (R = 0.77, p < 0.001). The SPECT and MRI ratios also 
correlated positively (R = 0.76, p < 0.001). 
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5. TREATMENT OF EXTRAPYRAMIDAL SIGNS 
 
Ten patients had UPDRS scores of 20 or more at the onset, and were started 
on levodopa therapy. Their mean age at the initiation of the treatment was 
16 years (range 13–23). In 1 year, the mean UPDRS decreased from 29 to 
26. However, there was quite wide variation in the response to levodopa, 
and in four cases the UPDRS score increased during the follow-up, while in 
three cases the decrease in the UPDRS score was 10 or more. Even in three 
of the four patients showing increased UPDRS scores at 1 year, a short-term 
benefit of levodopa was noticed, for at the 6-month visit the UPDRS score 
was below the baseline. 
 
Six patients had UPDRS scores of 10–19 and started therapy with selegiline; 
their mean age was 13 years (range 11–17). In the group with selegiline 
treatment, the mean UPDRS score at the onset was 13 and after 1 year on 
therapy 16. Individually, only two of the patients had a slight (2 and 3 
points) decrease in the UPDRS score. 
 
Five patients with a mean age of 15 years (range 14–16) had no therapy for 
their extrapyramidal symptoms. One of these patients received levodopa 
(50–100 mg/day) for one month, but the therapy was discontinued because 
of side effects. None of the other patients in this group received levodopa or 
selegiline on any occasion. In this group, the mean UPDRS score was 16 at 
the onset and after 1 year of follow-up, it was 26. In all but one patient the 
individual UPDRS score increased during the follow-up. 
  
When comparing the groups on different treatments, the change in the 
UPDRS score in patients on levodopa therapy was found to differ from that 
in the patients with no antiparkinsonian therapy (p=0.01). The change in the 
UPDRS score in the patients on selegiline treatment, on the other hand, did 
not differ from that in the patients on levodopa therapy (p=0.20) or in the 
patients with no antiparkinsonian treatment (p=0.16).  
 
In one case, therapy with levodopa was discontinued after 1 month while 
still in the titration phase, because of restlessness, agitation and frightening 
visual hallucinations. Otherwise, no side effects of levodopa were observed. 
As regards the patients on selegiline therapy, one patient had nausea at the 
initiation of the treatment. 
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DISCUSSION 
 
Juvenile neuronal ceroid lipofuscinosis is a progressive, neurodegenerative 
disease with multiple symptoms originating from the CNS, including mental 
decline, epilepsy and parkinsonian symptoms. Thus far, no curative 
treatment is available. However, we found that symptomatic drug treatment 
may bring about a relief in the everyday life of the patients, and so improve 
the quality of life. From a psychological point of view, despite the 
devastating disease process, even minor improvements are important. 
 
 
1. NEUROPSYCHOLOGICAL DECLINE 
 
The neuropsychological test battery used in the follow-up of patients with 
JNCL was found to be reliable, quick and easy to use. Furthermore, the 
children enjoyed the test.  
 
The first abnormal findings in the WISC-R were already noticed during the 
first years of the follow-up. Of the 14 patients included in study I, only four 
had an IQ of over 100 at the first evaluation. At this early stage, however, 
the decline in cognitive abilities was not noticeable in everyday life. Later 
on, the test results became increasingly abnormal, characterising the decline 
in the different cognitive functions. The best sub-item throughout the study 
was similarities, whereas digit memory span was found to decline most 
rapidly. This is in accord with an earlier study, in which the digit memory 
span was one of the first functions to become impaired (Lou and Kristensen 
1973) 
 
Except for one compound heterozygous male, only a few differences in the 
neuropsychological test battery were marked between homozygous and 
compound heterozygous patients. In light of the earlier reports, this was 
surprising (Järvelä et al. 1997). However, spatial orientation was impaired 
only in the homozygous patients. 
 
The increasing neurological dysfunction in patients with JNCL may result 
from accumulation of intracellular storage material. However, the precise 
pathogenesis is still unknown. Furthermore, other factors, including 
epileptic activity, may contribute to the mental and motor deterioration in 
JNCL. In MRI, progression of the disease was reflected as signal intensity 
changes and dilatation of the CSF spaces. However, the degree of atrophy 
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did not correlate with the severity of the clinical symptoms. Indeed, the 
neuropsychological findings seemed to reflect the progression of the disease 
better than the conventional MRI studies. Thus, functional impairment 
apparently precedes the structural abnormalities. 
 
The early mental impairment in JNCL emphasises the importance of early 
rehabilitation. One of the most important points is to teach Braille reading at 
an early stage, even if there is still enough vision for normal reading or 
reading with the help of visual aids. After the age of 10, learning Braille 
becomes difficult or even impossible, because of the short digit memory 
span, declining IQ, and motor impairment of the hands.  
 
 
2. EPILEPSY AND ANTIEPILEPTIC DRUG THERAPY 
 
The progressive myoclonic epilepsy in JNCL may sometimes be refractory. 
In the cross-sectional study of the epilepsy in JNCL, however, seizure 
control was satisfactory in most of the patients. The first epileptic seizure 
was noticed at the mean age of 10, the most common seizure types being 
generalised tonic-clonic seizures. No tendency was found for increasing 
seizure control with age, although this has been reported earlier (Boustany 
1992). 
 
AED therapy was first initiated as monotherapy, and the dose was titrated 
upwards until seizures decreased or side effects were observed. As the first 
AEDs, VPA, LTG, and FBM were found to be equally effective, when 
studied retrospectively. After LTG was proved valuable in JNCL, it was 
preferred as the first AED. Prior to this, valproate was used as the first-line 
AED, and was continued unless severe side effects developed.  
 
If seizure control was insufficient in monotherapy, despite the maximal 
doses tolerated, combination therapy was initiated. When choosing the 
additional AED, no specific strategy was applied. Thus, the groups on 
combination therapy in the cross-sectional study may be considered 
comparable. However, the size of each group was small, which may have 
influenced the results.  
 
Seizure control in patients with LTG monotherapy or LTG-CZP 
combination therapy was satisfactory in almost all the patients. However, 
the mean ages of these groups were low and thus progression of the disease 
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was still limited, which may have affected the results, although, in general, 
seizure frequency was not found to correlate with age. In VPA monotherapy 
or VPA-CZP combination therapy seizure control was satisfactory in most 
of the patients. Surprisingly, the majority of patients receiving combination 
of VPA and LTG had poor seizure control, despite the reported synergistic 
effect of these AEDs (Brodie and Yuen 1997) and the previous observation 
that this combination was effective in infantile NCL (Åberg et al. 1997).  
 
When examining the effects on the epilepsy of LTG, used either as 
monotherapy or in combination therapy, a decrease in the frequency or 
severity of seizures was found in about half of the patients and an increase 
in well-being in more than half. The different types of seizure responded to 
LTG treatment almost without exception, but severe myoclonia did not 
decrease or increase. This characterises the variable effect of LTG on 
myoclonia (Wallace 1990, Gibbs et al. 1992, Timmings and Richens 1993, 
Schlumberger et al. 1994). In two girls, in whom LTG was initiated because 
of the side effects of VPA, the seizure frequency increased during LTG 
monotherapy. Thus, in these cases, VPA was possibly more effective as 
monotherapy. In two other girls, in whom VPA was replaced by LTG, no 
change in the seizure frequency was observed. 
 
Side effects resulting in withdrawal of an AED were observed in a quarter 
of  the patients, mostly in patients on PB therapy, but also in patients on 
VPA or CZP therapy. However, in LTG therapy there were no withdrawals 
because of side effects. In addition to absence of severe side effects, LTG 
seemed to have favourable cognitive and behavioural effects in these 
patients, as also noticed in other studies on patients with intellectual 
disability (Besag 1999). 
 
 
3. EVALUATION OF EXTRAPYRAMIDAL SIGNS 
 
Patients with JNCL have gradually deteriorating motor impairment. 
Underlying the motor impairment, both pyramidal and extrapyramidal 
disturbances are seen (Hofman et al. 1999). However, the pyramidal signs, 
if noticed at all, are usually less marked.  
 
In all the patients with elevated UPDRS scores a reduced DAT density was 
found in the striatum, indicating nigrostriatal dopamine deficiency. The 
reduced DAT density was more pronounced in the putamen than in the 
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caudate, also a common finding in patients with idiopathic PD. A negative 
correlation was found between the UPDRS score and the DAT density in 
SPECT, which accords with the findings in patients with Parkinson’s 
disease (Seibyl et al. 1995, Rinne et al. 1995). This also accords with the 
PET study on nine patients with JNCL, in whom a correlation was found 
between extrapyramidal symptoms and a decline in [18F]fluorodopa uptake 
in the putamen (Ruottinen et al. 1997).  
 
In patients with Alzheimer´s disease, reduced [11C]β-CFT uptake was found 
as well, reduction of the uptake correlating with the severity of the 
extrapyramidal symptoms (Rinne et al. 1998). However, the putamen and 
the caudate nucleus were equally affected, in contrast to patients with JNCL. 
Therefore, the SPECT findings in patients with JNCL resemble those found 
in patients with Parkinson’s disease. 
 
The control subjects in the SPECT study were older than the patients with 
JNCL. As the transporter density is known to decline with age (Van Dyck et 
al. 1995), the decrease in striatal DATs in JNCL was presumably 
underestimated. However, as there are no β-CIT studies on healthy children 
under 18 years of age, it is not known whether the transporter ratio in 
children can be accurately extrapolated from studies on adults. In the present 
study, the striatal uptake of β-CIT was reduced even in patients 10-11 years 
of age. In the clinical evaluation, these patients usually had mild 
extrapyramidal symptoms, including impaired balance, slowing or reduction 
of the amplitude of hand movements and rigidity of the upper arms when 
activated by other movements. Thus, extrapyramidal symptoms seem to 
develop earlier than was previously reported by us (Järvelä et al. 1997), 
although, at this age, the symptoms may not have a noticeable effect on 
everyday life.  
 
The accumulations of β-CIT were calculated as striatum-to-cerebellum 
ratios, since accumulation in the cerebellum is considered non-specific. In 
JNCL, mild or moderate cerebellar atrophy usually appears after 14 years of 
age (Autti et al. 1996). Cerebellar changes might therefore influence the 
uptake ratios, although a marked effect is unlikely.  
 
In the brain, ß-CIT traces DATs, serotonin transporters (SERTs), and to 
some extent also noradrenaline transporters (Laruelle et al. 1994). Whereas 
DATs are situated predominantly in the basal ganglia, SERTs are found in 
the hypothalamus and midbrain (Ciliax et al. 1995, Jagust et al. 1996). 
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Indeed, ß-CIT binding in the striatum can be displaced by a DAT inhibitor 
but not by a SERT inhibitor (Laruelle et al. 1993). In the diencephalon and 
brainstem, on the other hand, the ß-CIT binding can be displaced by the 
SERT inhibitor, but not be the DAT inhibitor. Furthermore, the peak 
activity of ß-CIT in the hypothalamus-midbrain area is observed at 4 hours, 
whereas the striatal activity peaks at around 20 hours (Brucke et al. 1993). 
Therefore, ß-CIT binding to these two transporters can be differentiated by 
region of interest and by timing of imaging. In the present study, imaging 
was performed 24 hours after the injection and the regions of interest were 
drawn to the striatum, and thus, ß-CIT binding to SERTs can be considered 
minimal. 
 
Although first used to reveal the DATs in Parkinson’s disease, ß-CIT has 
also been employed to trace the SERTs. In patients with impulsive 
aggression (Tiihonen et al. 1997) and in alcoholics (Heinz et al. 1998), 
reduced SERT availability was found in the hypothalamus and midbrain, 
whereas DAT availability did not differ from controls. Surprisingly, in a ß-
CIT study on depressive children and adolescents, increased SERT 
availability was found, as compared with non-depressive children 
(Dahlström et al. 2000). Again, the striatal DAT availability in depressive 
and non-depressive children did not differ. In adult patients with major 
depression, however,  increased striatal DAT density was found (Laasonen-
Balk et al. 1999). In patients with JNCL, who often suffer from depression, 
SERT availability has not been studied thus far. 
 
Using MRI, increased striatum-to-thalamus signal intensity ratios were 
observed on the T2-weighted images. It is evident that the pathological 
process, also found in the thalamus (Autti et al. 1997), may interfere with 
this ratio. However, in a MRI study on patients with parkinsonism, it was 
impossible to distinguish the patients with non-idiopathic parkinsonism 
from those with idiopathic parkinsonism on the basis of signal intensity 
measurements, although the “signal intensity index” of the putamen was 
lower in the patients with secondary parkinsonism (Schwarz et al. 1999).  
 
The MRI signal intensity ratios showed a positive correlation with the 
clinical scoring and a negative correlation with the striatum-to-cerebellum 
ratios in SPECT. Thus, the more symptoms the patient had, the darker the 
thalami. These findings provide evidence for the contribution of thalamic 
dysfunction, in addition to nigrostriatal and striatal dysfunction, as the 
pathomechanism for the parkinsonian symptoms in JNCL. 
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4. ANTIPARKINSONIAN DRUGS 
 
The decrease in striatal dopamine transporter density offered a rational basis 
for a trial of dopaminergic drugs in the treatment of JNCL. In the open study 
on the effects of antiparkinsonian treatment on patients with JNCL, a 
favourable response to levodopa therapy in JNCL was observed, although 
there was great variation in this response. The design was open, since only 
limited data are available on the effect of levodopa and there are no data on 
the effect of selegiline in patients with JNCL. 
 
The patients for the different treatment groups were not selected randomly. 
The antiparkinsonian treatment depended on the UPDRS score. When the 
UPDRS score exceeded 10, selegiline was used, and when the score 
exceeded 20, the patient was given levodopa. Thus, in the levodopa group, 
the baseline UPDRS score was higher, reflecting further progression of the 
disease. In addition, the groups differed in genotype. In the control group, 
compound heterozygous patients were over-represented, whereas in the 
levodopa group, all the patients were homozygotes. As compound 
heterozygous patients may have a slower progression of extrapyramidal 
symptoms  (Järvelä et al. 1997), the positive effect of levodopa treatment 
found in the present study is further emphasised.  
 
In patients without any treatment for their parkinsonian symptoms, the mean 
UPDRS score increased more than in the group on selegiline, but this 
difference was not statistically significant. Thus, it is difficult to judge 
whether selegiline has an effect in JNCL or not. At least in Parkinson’s 
disease, selegiline has a favourable effect, which may be either 
symptomatic, neuroprotective, or both (Olanow et al. 1995, Schulzer et al. 
1992). 
 
Both levodopa and selegiline were generally well tolerated by patients with 
JNCL. However, in one patient on levodopa therapy, visual hallucinations, 
agitation, and anxiety occurred one month after initiation of levodopa. This 
patient had had psychotic behaviour even prior to the treatment, but since 
levodopa is known to induce psychosis, the therapy was discontinued and 
treatment was initiated with risperidone.  
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There were also two other patients with previous psychotic symptoms 
having levodopa treatment. However, when on continuous risperidone 
therapy, these patients had no aggravation of the psychotic symptoms during 
the levodopa therapy. These patients also responded to levodopa treatment, 
as did the patients without antipsychotic treatment. Although risperidone 
has an affinity for dopamine (D2) receptors, and it thus has the potential to 
induce extrapyramidal symptoms, the affinity is not of the same extent as in 
the case of older antipsychotics (Schotte et al. 1996). 
 
The results of the present study indicate a favourable effect of levodopa 
treatment in patients with JNCL, at least in the short term. This positive 
effect of dopaminergic drugs is in accord with the decreased striatal 
dopaminergic transporter density in JNCL. Since in JNCL there is also 
pathology in the thalamus and in the basal ganglia (Autti et al. 1996), it is 
understandable that the response to levodopa is milder and probably also of 
shorter duration than that seen in Parkinson’s disease. Therefore, in the 
future, long-term controlled trials are indicated to confirm the present 
results. 
 
 
5. POLYPHARMACY IN JNCL 
 
Because of the complicated clinical phenotype in JNCL, several CNS drugs 
are used simultaneously. This polypharmacy may give rise to unwanted 
interactions. 
 
In the use of AEDs, metabolic interactions are often seen. Some of the 
AEDs, including phenobarbitone, phenytoin, and carbamazepine, result in 
induction of hepatic enzymes. These AEDs are no longer used in Finnish 
patients with JNCL. Of the AEDs used at present, VPA has potential for 
inhibiting hepatic enzymes (Brodie 1992). Thus, in the concomitant use of 
VPA and LTG, the half-life of LTG is extended, and the doses must be 
adjusted (Yuen et al. 1992). On the other hand, LTG, which was found to be 
favourable in patients with JNCL, does not alter the metabolism of the other 
AEDs in general (Eriksson et al. 1996).  
 
A rare side effect seen in conjunction with the psychotropic polypharmacy, 
is the serotonergic syndrome (Bodner et al. 1995). This results from 
imbalance of the neurotransmitters, mainly the high serotonin, in the CNS. 
With the use of selective serotonergic inhibitors (SSRIs) alone or in 
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combination with monoamine oxidase (MAO) inhibitors, the serotonergic 
syndrome may occur. In some of the patients of the present series, 
citalopram was simultaneously used with selegiline, which is a MAO-B 
inhibitor. This did not result in any adverse effects. The concomitant use of 
citalopram and selegiline has also been well tolerated in healthy volunteers 
(Laine et al. 1997).  
 
Several of the CNS drugs, including antipsychotics, have been observed to 
induce electrocardiographic abnormalities, prolonging the QT time (Reilly 
et al. 2000). Citalopram may also induce unfavourable cardiac effects by 
impairing conduction and by shortening the repolarization time (Pacher et 
al. 1999). Electrocardiographic abnormalities are frequently found even in 
JNCL patients not taking drugs (Hofman et al. 1999, Hofman et al. 2001), 
and therefore, the role of the CNS drugs in producing electrocardiographic 
abnormalities in these patients remains unknown. 
  
In addition to unwanted interactions, the treatment of one symptom may 
have unfavourable effects on the other symptoms of JNCL. For instance, the 
psychotropic drugs may increase the extrapyramidal signs by blocking the 
dopamine receptors. Correspondingly, by increasing the dopamine levels 
necessary for alleviating extrapyramidal symptoms, the antiparkinsonian 
drugs may induce psychosis (Young et al. 1997). In one of the patients in 
our study, severe psychotic behaviour was observed 1 month after initiation 
of levodopa. Although the patient had had psychotic symptoms prior to the 
initiation of levodopa, the increased availability of the dopamine probably 
caused worsening of the psychotic symptoms.  
 
 
6. FUTURE PROSPECTS 
 
The ultimate goals in NCL research are to unravel the complete 
pathogenesis of these diseases and to find a curative treatment that would 
reverse the disease process. Meanwhile, in the near future, in order to avoid 
unnecessary polypharmacy, double-blind studies on the effects of drug 
therapy are indicated. This applies to both antiepileptic, antiparkinsonian, 
and psychotropic drug treatment. As the disease process is highly variable, 
and as any kind of medical intervention may result in temporary 
improvements, this affords a great challenge. 
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CONCLUSIONS 
 
1. The neuropsychological test battery developed for patients with JNCL 
was found to be reliable and easy to use, and offered valuable 
information on the progress of the disease. It also provided important 
guidelines for rehabilitation. 
 
2. The first epileptic seizure was noticed at a mean age of 10 years, the 
most common seizure types being generalised tonic-clonic seizures and 
complex partial seizures. As first line AEDs, VPA and LTG were found 
to be equally effective. However, adverse effects were less common 
with the use of LTG. Thus, AED treatment is based on LTG or VPA. In 
combination therapy, CZP is a valuable add-on AED. 
 
3. Extrapyramidal signs were already noticed at the age of 10 years. In ß-
CIT-SPECT, the mean striatum-to-cerebellum uptake ratio was 
significantly lower in patients than in controls, the decrease being more 
pronounced in the putamen than in the caudate nucleus. There was a 
negative correlation between the clinical scoring and the uptake ratios in 
SPECT. These findings indicate nigrostriatal dopaminergic 
hypofunction underlying the extrapyramidal symptoms. 
 
4. Levodopa treatment had a favourable effect on the extrapyramidal 
symptoms in patients with JNCL. Furthermore, levodopa was well 
tolerated. On selegiline therapy, the symptoms neither decreased nor 
increased. In patients with no treatment for the parkinsonism, the 
symptoms progressed. Thus, levodopa may be indicated in the treatment 
of extrapyramidal signs in patients with JNCL, but further studies are 
needed to confirm its definitive role in the treatment. 
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